secwatch.observer — SEC 8-K summary
======================================

Issuer:     HeartSciences Inc. (HSCS)
CIK:        0001468492
Form:       8-K
Filed at:   2023-03-16T23:59:59+00:00
Accession:  0000950170-23-008500
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

HeartSciences Q3 no revenue, $1.9M cash; progresses MyoVista FDA clearance, adopts equity plan
--------------------------------------------------------------------------------

- No meaningful Q3 FY2023 revenues; cash and equivalents $1.9M as of Jan 31, 2023.
- MyoVista pivotal validation study enrollment progressing for FDA De Novo resubmission; additional enrichment patients enrolled.
- Board adopted 2023 Equity Incentive Plan, subject to stockholder approval, covering employees, directors, and consultants.
- Collaboration with Rutgers University for AI-based ECG algorithms; patent portfolio now 40 (9 U.S., 31 international).
- Appointed microcap veteran David R. Wells to Board of Directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1468492/000095017023008500/0000950170-23-008500-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1468492/000095017023008500/hscs-20230316.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-008500

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer